Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Matricellular protein CCN3 mitigates abdominal aortic aneurysm
Chao Zhang, … , Domenick A. Prosdocimo, Zhiyong Lin
Chao Zhang, … , Domenick A. Prosdocimo, Zhiyong Lin
Published March 14, 2016
Citation Information: J Clin Invest. 2016;126(4):1282-1299. https://doi.org/10.1172/JCI82337.
View: Text | PDF | Erratum
Research Article Vascular biology

Matricellular protein CCN3 mitigates abdominal aortic aneurysm

  • Text
  • PDF
Abstract

Abdominal aortic aneurysm (AAA) is a major cause of morbidity and mortality; however, the mechanisms that are involved in disease initiation and progression are incompletely understood. Extracellular matrix proteins play an integral role in modulating vascular homeostasis in health and disease. Here, we determined that the expression of the matricellular protein CCN3 is strongly reduced in rodent AAA models, including angiotensin II–induced AAA and elastase perfusion–stimulated AAA. CCN3 levels were also reduced in human AAA biopsies compared with those in controls. In murine models of induced AAA, germline deletion of Ccn3 resulted in severe phenotypes characterized by elastin fragmentation, vessel dilation, vascular inflammation, dissection, heightened ROS generation, and smooth muscle cell loss. Conversely, overexpression of CCN3 mitigated both elastase- and angiotensin II–induced AAA formation in mice. BM transplantation experiments suggested that the AAA phenotype of CCN3-deficient mice is intrinsic to the vasculature, as AAA was not exacerbated in WT animals that received CCN3-deficient BM and WT BM did not reduce AAA severity in CCN3-deficient mice. Genetic and pharmacological approaches implicated the ERK1/2 pathway as a critical regulator of CCN3-dependent AAA development. Together, these results demonstrate that CCN3 is a nodal regulator in AAA biology and identify CCN3 as a potential therapeutic target for vascular disease.

Authors

Chao Zhang, Dustin van der Voort, Hong Shi, Rongli Zhang, Yulan Qing, Shuichi Hiraoka, Minoru Takemoto, Koutaro Yokote, Joseph V. Moxon, Paul Norman, Laure Rittié, Helena Kuivaniemi, G. Brandon Atkins, Stanton L. Gerson, Guo-Ping Shi, Jonathan Golledge, Nianguo Dong, Bernard Perbal, Domenick A. Prosdocimo, Zhiyong Lin

×

Figure 8

ERK1/2 pathway contributes to AAA formation in CCN3-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
ERK1/2 pathway contributes to AAA formation in CCN3-deficient mice.
(A) ...
(A) Maximal abdominal aortic diameter (left panel) and AAA incidence (right panel) in response to pharmacological inhibition of ERK1/2 by CI-1040 and JNK1/2 by SP600125 in KO mice. n = 5 for saline group; n = 13 for WT with Ang II; n = 22 for KO mice with Ang II; n = 20 for KO mice plus CI1040 group; n = 15 for KO mice plus SP600125 group. (B) Analysis of genetic inhibition of Erk1 on maximal abdominal aortic diameter (left panel) and AAA incidence (right panel) using Ccn3/Erk1 double-KO mice: Left panel, decrease of aortic expansion with Ang II treatment; right panel, AAA incidence, Ccn3–/–, n = 21; Ccn3–/– Erk1–/–, n = 18. Evaluation of elastin degradation (Ccn3–/–, n = 17; Ccn3–/– Erk1–/–, n = 7) (C), ROS production (Ccn3–/–, n = 5; Ccn3–/– Erk1–/–, n = 6) (D), MMP activity (Ccn3–/–, n = 9; Ccn3–/– Erk1–/–, n = 10) (E), and macrophage infiltration (n = 9) (F) in Ccn3/Erk1 compound-KO mice following Ang II infusion. Scale bars: 100 μm. For comparing AAA incidence, χ2 test was used; for all others, 2-way ANOVA followed by Bonferroni’s post-hoc correction was used.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts